• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Real World Evidence (RWE)

FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

by Jasmine Pennic 08/11/2020 Leave a Comment

FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

What You Should Know: The FDA and Syapse announce research collaboration expansion to address urgent public health challenges including supporting FDA’s goal of rapid understanding of COVID-19. As part of the research, Syapse is partnering with FDA’s Oncology Center of Excellence to investigate methods to derive RWD from multiple sources including electronic health records, registries and molecular data Syapse, a real-world evidence company accelerating the delivery of precision
Read More

Syapse Lands $30M to Accelerate Real-World Evidence in Oncology

by Fred Pennic 05/28/2020 Leave a Comment

Syapse Lands $30M to Accelerate Real-World Evidence in Oncology

What You Should Know: - Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine. - Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine. Syapse, a San Francisco, CA-based provider of precision oncology solutions announced $30
Read More

Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis

by Jasmine Pennic 11/04/2019 Leave a Comment

Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis

- IBM Watson Health and Aetion will combine the Aetion Evidence Platform with IBM MarketScan data to provide a turn-key solution for conducting regulatory-grade RWE analysis. - The partnership will satisfy mid-market companies’ demand to streamline the drug R&D process and will allow RWE to play a much greater role in support of companies’ drug portfolios. RWE can enable researchers to supplement clinical trials by optimizing the development of treatments, determining new indications for
Read More

McKesson, Aetion Partner on Real-World Evidence (RWE) in Cancer Research

by Jasmine Pennic 10/15/2019 Leave a Comment

Google Cancer Research

- Aetion and McKesson announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research. - Relationship pairs Aetion Evidence Platform and McKesson’s robust oncology data sets to accelerate regulatory-grade oncology studiesAetion and McKesson, today announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research to benefit patients, regulators, the biopharma industry, and payers. The partnership will
Read More

Life Image Launches Real World Imaging for RWE Programs

by Jasmine Pennic 09/05/2019 Leave a Comment

Life Image Launches Real World Imaging for RWE Programs

- Life Image launches Real World Imaging (RWI) offering to respond to researcher needs for maturing insights and accelerating drug development decisions.  - Imaging data, especially for Real World Evidence (RWE), has historically been difficult, if not impossible, to access, retrieve, view, de-identify and normalize at-scale, even though it provides clinically material insights for a growing number of therapies. - Life Image represents the only company providing large, heterogeneous,
Read More

FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)

by Jasmine Pennic 08/14/2019 Leave a Comment

FDA Cancer COE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)

Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of real-world evidence (RWE) to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine.Methods to Derive RWE From Multiple
Read More

Litmus Health Launches Next-Generation Data Science Platform for Clinical Research

by Fred Pennic 08/07/2019 Leave a Comment

Litmus Health Launches Next-Generation Data Science Platform for Clinical Research

 Litmus Health, the research-ready infrastructure platform for real-world data has announced the release of the next generation of their platform focused on reliable data engineering, data quality, and flexible deployment. The end-to-end platform supports the entire trial process: from data collection at the point of experience to laboratory analytics that can inform decision making.Pharma Industry Increasingly Turning to Real-World DataThe pharmaceutical industry has been increasingly looking
Read More

SHUH, Syapse to Build South Korea’s First Real-World Data Sharing Network for Precision Oncology Hospitals

by Jasmine Pennic 08/06/2019 Leave a Comment

SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data-sharing network for leading precision oncology hospitals in the region. Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH), a South Korea-based hospital, today announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will
Read More

BHE Raises $78M To Expand Real-World Evidence Analytics Platform

by Fred Pennic 05/15/2019 Leave a Comment

BHE Raises $78M To Expand Real-World Evidence Analytics Platform

BHE, a Boston, MA-based innovative healthcare analytics company, today announced a $78 million minority growth investment led by Silversmith Capital Partners (“Silversmith”) and Leerink Transformation Partners (“LTP”). Instant Health DataThe use of real-world evidence (RWE) has grown rapidly within life sciences companies over the last several years, supported by the proliferation of large datasets, new computing technologies, and interest by both payers and regulatory agencies in understanding
Read More

TriNetX Acquires European Clinical Data Network InSite

by Jasmine Pennic 04/02/2019 Leave a Comment

TriNetX Acquires European Clinical Data Network InSite

TriNetX, a global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE) has acquired Belgium-based Custodix NV and its InSite network. InSite network is a European-based provider of services for clinical trial design, patient feasibility, and enabling workflow for patient recruitment. Financial details of the acquisition were not disclosed. InSite Clinical Data Network Background The InSite platform is an
Read More

  • Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |